Cytotoxic drug conjugates and their delivery to tumor cells

• US 5,087,616 A
• Filed: 08/06/1987
• Issued: 02/11/1992
• Est. Priority Date: 08/07/1986
• Status: Expired due to Fees

• Current Assignee: Battelle Memorial Institute
• Original Assignee: Battelle Memorial Institute
• Inventors: Bichon, Daniel, Myers, Andre E.
• Primary Examiner(s): Moezie, F. T.
• Application Number:
  US07/082,244
• Time in Patent Office: 1,650 Days
• Field of Search: 530/345, 530/399, 530/408-410, 530/389-391, 514/21, 514/12
• US Class Current: 514/7.6
• CPC Class Codes: A61K 47/642 the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
• CPC Class Codes: A61K 47/645 Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
• CPC Class Codes: A61P 35/00 Antineoplastic agents

Abstract

A therapeutic composition comprising a chemical conjugatge including a first moiety, other than an immunoglobulin or fragment thereof, such as epidermal growth factor, which preferentially binds to a tumor cell, and is internalized by the cell, and a second moiety linked to the first moiety, and comprising a biodegradable polymeric carrier, such as polyglutamic acid, to which one or more cytotoxic molecules, for instance, daunomycin, are attached. The degradation of the carrier by intracellular enzymes releases a cytotoxic agent, resulting in selective destruction of the tumor cells.

Claims

1. A therapeutic chemical conjugate including EGF as a first moiety, and a second moiety linked covalently to the EGF, said second moiety comprising a plurality of repeating units, each unit having the structure ##STR12## where L is selected from the group consisting of polyglutamic acid and polyaspartic acid, and T is selected from the group consisting of anthracycline drugs, bleomycin, melphalan, chlorambucil, cisplatin, adriamycin, daunomycin, and daunorubicin, and where said conjugate has a molecular weight of between 10,000 and 100,000 D and is effective in target cells in vivo and is internalized by tumor cells whereby the latter are inhibited or destroyed.

2. The conjugate of claim 1 wherein L is polyglutamic acid and T is daunomycin.

3. The conjugate of claim 1, where the EGF is essentially identical to human EGF.

4. The conjugate of claim 1, wherein the first moiety is directly linked to the second moiety by means of a peptidyl linkage.

5. The conjugate of claim 1 wherein the first moiety is linked to the second moiety by a structure having the formula:

##STR13## where R'"'"' is;

alkylene (C₁ -C₄);

1,3-phenylene;

cyclohexylene-4-methylene;

or alkylene (C₁ -C₄)-phenylene (1,4); and

m=1 or 2.

6. The conjugate of claim 1, having a molecular weight of less than about 100,000 D.

7. The conjugate of claim 1 wherein the T is selected from the group consisting of anthracycline drugs, bleomycin, melphalan, chlorambucil, and cisplatin.

8. The conjugate of claim 7 wherein the T is selected from the group consisting of adriamycin, daunomycin, and daunorubicin.

9. The conjugate of claim 1 wherein the T is daunomycin.

10. A therapeutic composition comprising the chemical conjugate of claim 1 and a therapeutically acceptable carrier having a molecular weight of between 10,000 and 100,000 D.